Vlad Research Group
Anda Vlad, MD, PhD
The Vlad Lab has recently generated valuable preclinical models for endometriosis and ovarian cancer using double and triple transgenic mice, respectively. The lesions in mice closely mimic those found in humans and express the human MUC1 tumor-associated antigen, a protein that can promote tumor formation.
MUC1 has been tested in numerous worldwide clinical trials as a cancer vaccine candidate. Using new animal models, MUC1 roles in ovarian tumor formation can be idenitified and a new MUC1 vaccine as therapy in ovarian cancer can be tested. Furthermore, novel MUC1 vaccines can also be tested for their potential in cancer prevention in mice with cancer predisposing-lesions (endometriosis).
Proposing to identify immune biomarker discovery for disease management of endometriosis and ovarian cancer, the lab is investigating numerous questions about immune surveillance in women with these diseases. Via collaborations with our clinician colleagues at Magee-Womens Hospital of UPMC, the lab is working on implementing new clinical trials exploring the roles of novel immune biologics as adjuvant therapy in ovarian cancer.
Raluca Budiu, PhD
Swati Suryawanshi, PhD
Jessica Craig, BS
- Budiu R, Diaconu I, Dricu A, & Vlad AM. Modulation of human mucin 1 (MUC1) tumor-associated antigen in a syngeneic, transplantable, ovarian cancer transgenic mouse model. Biol and Therapy of Cancer Cell, 2010 (in press).
- Budiu R, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Finn OJ, & Vlad AM. Mice progressing to human mucin 1 (MUC1)-positive ovarian endometriosis-like lesions develop anti-MUC1 antibodies and show increased Foxp3 positive T cells in regional lymph nodes. Dis Model Mech, 2(11-12):593-603, Nov.-Dec., 2009.
- Vlad, AM,Budiu R, Thaller J, Finn OJ, & Edwards, RP. Immune monitoring of ovarian cancer patients treated with intraperitoneal IL-2 shows correlations of serum anti-MUC1 antibodies. Cancer Immunol Immunother, Aug. 19, 2009 [Epub ahead of print].
- Ryan SO, Vlad A, Jean Gariépy, & Finn OJ. Tumor-associated glycopeptides of the tumor antigen MUC1 are not subject to self-tolerance and improves immune responsiveness in the MUC1 transgenic mouse. Biol Chem,390(7):611-8, Jul. 2009.
- Vlad A, Diaconu I, & Gantt, KR. MUC1 in endometriosis and ovarian cancer. Immunol Res, 36(1): 229-36, 2006.
- Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, & Finn OJ. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunol, 108(1): 32-41, 2003.
- Vlad A, Kettel J, Alajez N, Carlos C, & Finn OJ.Review article“MUC1 Immunobiology: From discovery to clinical applications”.Adv Immunol, 82: 249-93, 2003.
- Vlad A, Muller S, Cudic M, Paulsen H, Otvos L, Georg-Hanisch F, & Finn O. Complex Glycans remain intact during the processing of MUC1 glycopeptides by dendritic cells and affect T cell recognition of MHC class II-restricted peptides. J Exp Med, 196(11): 1435-46, 2002.